MDWD

Business Context and Reporting Period

Company: MediWound Ltd. (Nasdaq: MDWD)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: MediWound is a biopharmaceutical company developing enzymatic therapeutics for tissue repair. Its flagship product, NexoBrid, is approved in over 45 countries for eschar removal in severe burns. The company is advancing EscharEx, a therapy for chronic wounds, currently in a pivotal Phase III trial (VALUE study). Operations are headquartered in Yavne, Israel, with a manufacturing facility that reached full operational capacity in late 2025, increasing output sixfold.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The filing text states total cash, cash equivalents, and short-term/restricted bank deposits were $53.6 million as of Dec 31, 2025. The table above reflects the specific line items from the Consolidated Statements of Financial Position ($4.8M cash + $48.3M short-term deposits + $0.4M long-term restricted deposits).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 16% to $16.96 million. This was driven by a 15% drop in product sales (primarily lower sales to U.S. partner Vericel) and an 18% drop in development service revenue due to U.S. government shutdowns delaying budget approvals and contract initiations.
• Increased R&D Spend: Research and development expenses surged 61% to $14.32 million, primarily due to costs associated with the EscharEx VALUE Phase III trial.
• Financial Income: Net financial income improved significantly to $1.56 million (from a $10.76 million expense in 2024), driven by a $2.16 million gain from the revaluation of warrants.
• Manufacturing Expansion: The new GMP-compliant manufacturing facility in Yavne reached full operational capacity in late 2025, increasing production output sixfold. Commercial availability is pending regulatory approvals expected in 2026.
• Capital Raise: In September 2025, the company completed a registered direct offering of 1.73 million shares at $17.30 per share, raising approximately $30.0 million in gross proceeds.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Liquidity: Management believes existing cash and deposits ($53.6 million) are sufficient to fund operations and capital expenditures for at least 12 months from the report date.
• EscharEx: The pivotal Phase III VALUE trial for venous leg ulcers is underway with enrollment completion expected by year-end 2026. A Phase II study for diabetic foot ulcers is planned for the second half of 2026.
• NexoBrid: The company expects to secure regulatory approvals for the expanded manufacturing facility in 2026 to meet growing global demand.

Key Risks and Contingencies:

• Geopolitical Instability: The company faces significant risks from ongoing conflicts in the Middle East (Israel, Gaza, Lebanon, Iran). While operations have continued without material disruption, escalation could impact workforce availability (reserve duty), supply chains, and manufacturing continuity.
• Single Manufacturing Site: All manufacturing occurs at a single facility in Yavne, Israel. A force majeure event (war, fire, equipment failure) could halt all production.
• Single Supplier: The company relies on a sole supplier in Taiwan (Challenge Bioproducts Corporation) for bromelain SP, a key intermediate drug substance. Political tensions or supply disruptions in Taiwan pose a material risk.
• Government Funding: A significant portion of revenue comes from U.S. government contracts (BARDA, DoW/MTEC). These contracts are subject to termination at the government's discretion and are impacted by U.S. government shutdowns.
• Regulatory Approval: Commercial success depends on the successful completion of clinical trials and regulatory approvals for EscharEx and the expanded NexoBrid facility.

Investor Verification Checklist

• Manufacturing Capacity: Verify the timeline for regulatory approval of the expanded Yavne facility to confirm when the sixfold capacity increase will translate to commercial sales.
• EscharEx Trial Progress: Monitor enrollment rates and interim data from the VALUE Phase III trial (targeting 216 patients) to assess the likelihood of regulatory approval.
• Geopolitical Exposure: Assess the impact of ongoing regional conflicts on the company's ability to maintain operations in Israel and secure supply from Taiwan.
• Government Contract Renewals: Track the status of BARDA and DoW/MTEC contracts, as these expired or are expiring in late 2025, and determine if new funding agreements have been secured.
• Cash Burn Rate: Monitor the rate of cash consumption given the increased R&D spend and the company's history of net losses to validate the 12-month liquidity runway.